Amgen Statement on Aranesp Manuscript in the Journal of Clinical Oncology
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Jan. 28, 2008--Amgen
(NASDAQ:AMGN) issued the following statement on the publication of an
Aranesp(R) (darbepoetin alfa) manuscript in the January 28, 2008,
online issue of the Journal of Clinical Oncology. Amgen anticipates
this manuscript will be available in the March 1, 2008, print edition.
"The '103 Anemia of Cancer' study, a Phase 3 trial designed to
test whether anemic patients with active cancer not receiving
concurrent chemotherapy or radiotherapy benefit from treatment with
Aranesp, was previously reported by Amgen when results became
available in 2007. The results of this study were provided to
regulatory agencies, communicated to physicians through a 'Dear
Healthcare Provider' letter, and presented at a scientific conference
and other venues throughout last year.
"Amgen is committed to ensuring physicians and their patients have
the most up-to-date information on its medicines, including both
positive and negative results from clinical trials."
Amgen, Thousand Oaks
Ashleigh Koss, 805-313-6151 (media)
Arvind Sood, 805-447-1060 (investors)